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Speciﬁc regions of the Alzheimer’s disease (AD) brain are burdened with extracellular protein deposits, the accumulation of which
is concomitant with a complex cascade of overlapping events. Many of these pathological processes produce oxidative stress.
Under normal conditions, oxidative stress leads to the activation of defensive gene expression that promotes cell survival. At the
forefront of defence is the nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that regulates a broad spectrum
ofprotectivegenes.Glycogensynthasekinase-3β(GSK-3β)regulatesNrf2,thusmakingthiskinaseapotentialtargetfortherapeutic
intervention aiming to boost the protective activation of Nrf2. This paper aims to review the neuroprotective role of Nrf2 in AD,
withspecialemphasisontheroleofGSK-3β intheregulationoftheNrf2pathway.WealsoexaminethepotentialofinducingGSK-
3β by small-molecule activators, dithiocarbamates, which potentially exert their beneﬁcial therapeutic eﬀects via the activation of
the Nrf2 pathway.
1. Alzheimer’s Disease andOxidativeStress
Alzheimer’s disease is a common age-associated dementia
characterized by pathological, progressive loss of neurons
and synapses, accumulation of intra- and extracellular pro-
tein deposits, and gliosis. The amyloid hypothesis of ADpos-
tulates that amyloid-beta (Aβ) deposition and neurotoxicity
play a causative role in AD [1]. Although the mechanisms
through which Aβ exerts its toxicity are numerous [2], it
appears that oxidative injury is central in the pathogenesis
of AD [3–5].
Oxidative stress results from an imbalance between
the production and removal of physiologically important
molecules collectively called reactive oxygen species (ROS)
[6–8]. Oxidative stress damages all cellular macromolecules
and when uncontrolled, leads to irreparable oxidative injury
and cell death. The imbalance between the production and
removal of ROS occurs when endogenous defence systems
are overwhelmed or exhausted, usually due to disease or
as part of normal aging. It is thus not surprising that
oxidative stress is involved in the pathogenesis of several
neurodegenerative disorders, including AD.
Oxidative stress is a central feature of AD, and, in fact,
it may even be one of the ﬁrst pathogenic events during
disease progression [5]. Markers of oxidative damage such
as protein carbonyls [9, 10] and elevated lipid peroxidation
[11, 12] precede pathological changes and are found in the
brains of AD patients. Importantly, antioxidant defence is
impaired in mouse models of AD; the levels and activities of
protective enzymes including superoxide dismutase (SOD)
and glutathione peroxidase are altered [13].2 International Journal of Alzheimer’s Disease
2.GSK-3β andAD
GSK-3β is a serine/threonine kinase that regulates diverse
cellular functions ranging from glycogen metabolism to gene
transcription and cell survival [14, 15].
Several lines of evidence directly link GSK-3β to the
neuropathology of AD [14, 16, 17]. In fact, the recently
described GSK hypothesis of AD depicts how overactivation
of GSK-3β accounts for the pathology of AD [16]. GSK-3β
expression is elevated in the brain of AD patients and is
implicated with at least three major pathological hallmarks
ofthedisease[18,19].First,overactivityofGSK-3βaccounts,
atleastinpart,fortauhyperphosphorylation[20].Inhuman
brain, active GSK-3β has been detected in neurons loaded
with neuroﬁbrillary tangles [21], and in vitro evidence link
increased GSK-3β activation to tau hyperphosphorylation.
In fact, Aβ can activate GSK-3β, leading eventually to
increased tau phosphorylation and loss of microtubule
binding. In agreement with the in vitro evidence, mice
overexpressing GSK-3β display prominent tau hyper-
phosphorylation [22]. Secondly, acetylcholine synthesis is
suppressed by GSK-3β, thus implicating the kinase in the
cholinergic deﬁcit characteristic of the disease [23]. This
eﬀect has been shown to be mediated by GSK-3β-dependent
inactivation of pyruvate dehydrogenase (PDH), leading to
the depletion of acetyl coenzyme A, an important precursor
in acetylcholine synthesis [23]. Thirdly, overactivity of the
kinase causes increased production of toxic Aβ.G S K - 3 β
has been shown to interact with presenilin, thus increasing
the production of the amyloid precursor protein (APP) and
subsequently toxic Aβ. The increased production of Aβ then
leads to synaptic deﬁcits and memory impairment [24–27].
GSK-3β can also directly phosphorylate APP in vitro [28],
and, interestingly, AD-related mutated presenilin-1 is able
to both directly and indirectly activate GSK-3β [29, 30].
Not surprisingly, the inhibition of GSK-3β blocks the
accumulationof Aβ andreducesplaqueburdenintransgenic
mice modelling AD [24], while the overexpression of GSK-
3β causes memory deﬁcits [31, 32]. Certain antibodies that
reduce brain Aβ burden also mediate their protective eﬀect
by inhibiting GSK-3β activation [33]. Finally, GSK-3β is an
important mediator of apoptosis [34], thus its dysregulation
may also directly contribute to AD-associated neuronal loss.
GSK-3β phosphorylates a diverse group of substrates,
including over 20 transcription factors [14, 35]. It is
hypothesized that GSK-3β-mediated impaired activation of
transcription factors compromises the ability of cells to
respond adequately to stressful conditions. Indeed, GSK-3β
is inhibitory towards the activation of transcription factors
such as heat shock factor-1 [36, 37] and cyclic AMP response
element-bindingprotein[14,38],whichareimportantincell
survival mechanisms after potentially toxic insults [39–41].
However, it is important to note that GSK-3β activation may
also aﬀect cell survival by other mechanisms. For example,
activated GSK-3β can inactivate an important mediator in
the citric acid cycle, PDH, and may thus impair the energy
supply in neurons [23].
As the majority of the transcription factors controlled
by GSK-3β are involved in cellular survival pathways, the
modulation of transcription factors by GSK-3β is likely
an important survival mechanism against various stresses,
including oxidative stress. It is interesting to note that oxida-
tive stress itself may also be related to GSK-3β activation.
For example, oxidative stress induces overactivation of GSK-
3β in neuronal cells [42], while the inhibition of GSK-3β
is involved in the control of oxidative stress in neuronal
hippocampal cell lines [43].
3. Endogenous Defence against OxidativeStress
Under normal conditions, oxidative stress leads to the
activation of a battery of defensive gene expression that
leads to detoxiﬁcation, prevention of free radical generation
and cell survival [44]. At the forefront of defence against
oxidative stress is the transcription factor named nuclear
factor erythroid 2-related factor (Nrf) 2. Human Nrf2
was ﬁrst isolated in 1994 from a hemin-induced K562
erythroid cell line and showed high sequence speciﬁcity to
the known p45 subunit of NF-E2 [45, 46]. Nrf2 regulates
a broad spectrum of enzymes and proteins involved in the
disposition of harmful compounds causing oxidative stress.
The classes of genes regulated by Nrf2 aﬀect such diverse
functions as detoxiﬁcation of electrophiles, free radical
metabolism, glutathione metabolism, proteasome function,
and calcium homeostasis [47]. Microarray analyses have
revealed numerous Nrf2-dependent genes that confer pro-
tection against oxidative stress in vitro [48, 49, 49, 50]. Some
of the well-characterized cytoprotective genes controlled by
Nrf2 include heme oxygenases (HOs), NAD(P)H:quinone
oxidoreductases, superoxide dismutases (SODs) and the
rate-limiting enzymes of glutathione synthesis consisting of
catalytic (GCLC) and modiﬁer (GCLM) subunits [51–53].
Transcription factors such as Nrf2 are considered key
targets of numerous signalling pathways because they have
the critical role of transferring information from the extra-
cellular environment to the nucleus to regulate multiple
functions. The induction of the Nrf2-controlled protec-
tive response requires at least three essential components;
antioxidant response elements (AREs), Nrf2, and Kelch
ECH-associating protein 1 (Keap1) [47]. AREs are enhancer
sequences that control the basal and inducible expression of
protective genes in response to oxidative stress, xenobiotics,
heavy metals and ultraviolet light [44, 54, 55]. Nrf2 is the
principal transcription factor that binds to the ARE and
induces the expression of ARE-driven cytoprotective genes.
Keap1 is a cytosolic, actin-associated protein that suppresses
the activity of Nrf2 by sequestering it in the cytoplasm and
by targeting it for proteasomal degradation.
The abundance of Nrf2 inside the nucleus is constantly
regulated by positive and negative stimuli that aﬀect nuclear
import and export, binding to the ARE, as well as the
degradation of Nrf2 [44]. It is well known that Keap1 [56]
is an inhibitor of Nrf2 that targets Nrf2 for degradation and
thus promotes low, basal expression of cytoprotective genes
under normal physiological conditions. Previously, it was
thought that oxidative stimuli activate Nrf2 by promoting
its dissociation from Keap1; however, as the binding aﬃnity
between the two proteins is not aﬀected by oxidative stressInternational Journal of Alzheimer’s Disease 3
[57–59], it is now understood that the main function of
Keap1 is to serve as an adapter for the Cullin3/Ring Box 1 E3
ubiquitin ligase complex [60, 61]. Keap1 binding to Cullin3
andNrf2leadstotheubiquitinationanddegradationofNrf2
through the 26S proteasome [62, 63]. Keap1 also functions
as ROS sensor molecule, the cysteine residues of which
are modiﬁed upon conditions of oxidative stress [64, 65].
OxidativestressimpairstheabilityofKeap1totargetNrf2for
degradation, most likely by triggering an alteration in Keap1
conformation.
4. Nrf2 inAD
The activation of the Nrf2-ARE pathway is beneﬁcial in
animal models of various diseases of the central nervous
system,includingchronicneurodegenerativediseasessuchas
Parkinson’s disease and acute insults such as brain ischemia
and brain trauma [66–69]. However, in comparison to other
neurodegenerative disorders, the role of Nrf2 in AD has
received relatively little attention. Currently, it is known that
while Nrf2 is not a susceptibility gene for AD, common vari-
antsofthegeneencodingNrf2mayaﬀectdiseaseprogression
[70]. In the human AD brain, the amount of nuclear Nrf2
is reduced in the hippocampus [71]. Histochemical analyses
demonstrate that Nrf2 predominantly localizes to the
cytoplasm of AD-aﬀected hippocampal neurons, suggesting
that despite oxidative stress, Nrf2-mediated transcription
is not induced in AD patients. However, this study utilized
brain tissue demonstrating full-blown AD pathology; it is
not clear whether the ﬁnding is a cause or consequence of
the ongoing pathological events and cell death. In fact, it has
been suggested that the induction of Nrf2, and levels and
activity of its cytoprotective target enzymes may display a
time-dependent alteration in AD [66].
We recently showed that attenuation of the Nrf2-ARE
pathway coincides with disease progression in the APdE9
transgenic mice modelling AD [72]. The Nrf2-pathway
was impaired in transgenic AD mice concomitantly with
increased brain Aβ burden. This AD-associated reduction
in Nrf2 was recently conﬁrmed by Choudry et al., who
described a 50% reduction in Nrf2 levels in transgenic AD
mice [73].
A growing body of literature suggests that Nrf2 is
neuroprotective in AD. Induction of the Nrf2-ARE pathway
by small therapeutic molecules protects against neuronal
dysfunction and toxicity mediated by Aβ in vitro [72, 74–
76]. Interestingly, Nrf2 can also exert its protective eﬀects by
suppressing oxidative stress-induced Aβ formation [74, 77]
and by inducing the 26S proteasome, thus facilitating the
removal of toxic Aβ [78]. Protection against Aβ toxicity by
coﬀee extract has also been shown to occur via the induction
of the Nrf2-ARE pathway in Caenorhabditis elegans [79].
In addition to assessing the eﬀect of small molecule
inducersoftheNrf2-AREpathwayonAβtoxicity,werecently
studied therapeutic and disease-modifying properties of
Nrf2-ARE induction by gene transfer in transgenic mice
modelling AD [80]. The long-term eﬀect of Nrf2-ARE
activation was studied in vivo by employing a gene therapy
approach where human Nrf2 was directly injected into the
hippocampi of transgenic AD mice, an area of the brain
important for learning and memory that is directly aﬀected
by AD pathology. Evident improvement in cognitive abilities
was achieved when transgenic AD mice were treated with the
Nrf2 vector at the age of 9 months and assessed in the Morris
water maze 6 months later. This eﬀect was associated with
the induction of the Nrf2-pathway, suggesting that strategies
aimed at boosting the Nrf2-ARE pathway constitute a
potential therapeutic approach for AD.
5.GSK-3β inthe Regulation of
the Nrf2-ARE Pathway
As GSK-3β controls a variety of targets in several cellular
pathways,itisnotsurprisingthatthekinaseisalsoimplicated
in the regulation of Nrf2. GSK-3β exerts a negative form of
regulation on Nrf2 by controlling it is subcellular distribu-
tion[81]( Figure 1). Long-term exposure to hydrogen perox-
ide causes downregulation of Akt, activation of GSK-3β,a n d
translocation of Nrf2 from the nucleus to the cytosol, thus
limiting the antioxidant response of cells [82]. This is partic-
ularly important in conditions of prolonged oxidative stress,
such as AD, and highlights the importance of this kinase
in chronic neurodegenerative disorders. The inhibition of
GSK-3β results in nuclear accumulation and the elevation of
transcriptional activity of Nrf2 [82], indicating that GSK-3β
is a fundamental element of Nrf2-ARE downregulation after
oxidative injury. The mechanism of GSK-3β-mediated Nrf2
inhibition appears to involve the tyrosine kinase Fyn, which
is phosphorylated by activated GSK-3β and leads to nuclear
localization of Fyn. Activated Fyn phosphorylates tyrosine
568 of Nrf2 [83] in the nucleus, leading to Nrf2 export
and dampening of protective gene transcription [83, 84].
Once excluded from the nucleus, Nrf2 is degraded. Very
recently, it was shown that transfection with a constitutively
active genetic variant of GSK-3β completely inhibits nuclear
accumulation of Nrf2, providing further support for the role
of GSK-3β in controlling Nrf2 activation [85].
Further evidence for the importance of GSK-3β in the
regulation of Nrf2 is demonstrated by the ﬁnding that acti-
vationofthemuscarinicM1receptorinducesNrf2througha
signalling cascade involving protein kinase C-mediated inhi-
bition of GSK-3β [86]. Moreover, GSK-3β is known to reg-
ulate oxidative stress protein SKN-1, the functional counter-
part of Nrf2, in Caenorhabditis elegans [87]. Taken together,
these data suggest that increased activation of GSK-3β leads
to a dampening of the protective Nrf2-ARE pathway.
6.DithiocarbamatesasNrf2-Inducing
Pharmacological Agents Targetedto
GSK-3β Activation
Stimulation of the Nrf2-ARE pathway by small-molecule
activators represents an appealing strategy to upregulate the
endogenous defence mechanism of cells against oxidative
stress. At least nine classes of Nrf2 inducers have been
described [88] and several of these are protective in models
of neurodegenerative diseases. However, more potent, safe,4 International Journal of Alzheimer’s Disease
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Figure 1: Induction of the Nrf2-ARE pathway under normal and pathological conditions: potential role of GSK-3β as a negative regulator
of Nrf2. (a) In normal conditions, actin-associated Keap1 sequesters Nrf2 in the cytosol and targets it for degradation. (b) Endogenously
and exogenously generated ROS alter the interaction between Nrf2 and its repressor, resulting in the accumulation of Nrf2 in the cytoplasm.
Nrf2 translocates into the nucleus. (c) An abundance of Nrf2 in the nucleus results in the binding of Nrf2 to the ARE and the increased
expression of protective, Nrf2-controlled genes. (d) In conditions of prolonged oxidative stress, GSK-3β is activated. (e) Activated GSK-3β
phosphorylates Fyn, causing nuclear translocation. (f) Nuclear Fyn phosphorylates Nrf2, leading to nuclear export of Nrf2 and degradation
in the cytosol.
and speciﬁc activators of the Nrf2-ARE pathway that cross
thebloodbrainbarrier(BBB)needtobeexploredinrelevant
models of AD.
Dithiocarbamates are attractive drug candidates for
many diseases as they are BBB permeant metal chelating
compounds that possess antioxidant and anti-inﬂammatory
properties [89] and are clinically approved for treatment
of alcohol addiction (Antabus) and heavy metal poisoning.
In addition to its well-characterized role in the inhibition
of nuclear factor-κB[ 90, 91], pyrrolidine dithiocarbamate
(PDTC) has potent antioxidant properties and is able to
scavenge ROS [90–93]. It is becoming increasingly evident
that PDTC also has the potential to activate endogenous
antioxidant gene expression. In vitro studies suggest that
PDTC treatment results in the activation and nuclear
translocation of Nrf2 [94, 95]. Moreover, the cytoprotective,
Nrf2-controlled proteins, HO-1, GCLM, and SOD, are
potently induced in response to PDTC in vitro [94, 96–98].
Interestingly, it has also been shown that PDTC can act as a
pro-oxidant [99]. Indeed, PDTC induces apoptosis in several
in vitro models [100, 101, 101, 102] and may also be toxic
to neurons in vivo [103]. Whether the action of PDTC is
anti-orpro-oxidanthasbeenreportedtodependonthedose
of PDTC and the presence of metal ions [104]. It may well
be that PDTC can exert its eﬀects on Nrf2-mediated gene
transcription by mimicking an oxidative insult (and thus
acting as a pro-oxidant) that triggers Nrf2 activation.
PDTC is known to reduce activated GSK-3β signalling
in neonatal hypoxia-ischemia [105]. We also showed that
while the activity of GSK-3β is increased in the brains of
transgenic AD mice [106], a 7-month treatment with PDTC
reduces the amount of active GSK-3β with concomitant
improvement in the spatial learning of the treated mice. This
eﬀect may involve the metal-chelating ability of PDTC. It is
known that PDTC can transport extracellular copper into
cells [107] and depending on the situation at hand, this may
have diﬀerent eﬀects. For example, copper transport into
cellsismostlikelybeneﬁcialinADanimalmodels[108–110],
where pools of intracellular copper are depleted or unevenly
or ineﬃciently distributed within the brain parenchyma. In
contrast, under normal conditions, an increase in cellular
copperlevelsmaycauseanincreaseinfreeradicalproduction
and apoptosis [111, 112]. As copper can induce the Akt
pathway, we hypothesize that the PDTC-mediated increase
in intracellular copper could trigger the phosphorylation of
Akt, leading to reduced GSK-3β activity.
To analyze the association of Nrf2 with the beneﬁcial
eﬀect of PDTC treatment, we assessed the potential ofInternational Journal of Alzheimer’s Disease 5
PDTC in protection against Aβ toxicity in primary cultures
prepared from Nrf2 knockout mice. While PDTC protected
against Aβ toxicity in wild-type neuronal cultures, the
beneﬁcial eﬀect was abolished in cultures prepared from
knock-out mice (Kanninen, K et al., unpublished data).
Moreover, PDTC treatment of neuronal cultures induced
Nrf2 target genes (Kanninen, K et al., unpublished data).
Taken together, these data indicate that Nrf2 is required for
the beneﬁcial eﬀect of PDTC against Aβ toxicity in vitro and
suggest that Nrf2-ARE induction may be associated with the
beneﬁcial eﬀect of PDTC in AD. However, further studies are
required to clarify and specify the involvement of GSK-3β in
aberrant regulation of Nrf2 in AD.
7.TargetingGSK-3β for Therapeutic Beneﬁt in
AD: Involvement of the Nrf2-ARE Pathway
While the detailed mechanisms behind the impairment of
the Nrf2-ARE pathway in transgenic AD mice remain unre-
solved,itispossiblethatitinvolvesGSK-3β.Consideringthat
GSK-3β caninactivateNrf2[81,86],itisconceivablethatthe
Nrf2-ARE pathway is dampened in the aged AD transgenic
mouse brain through the increased activity of GSK-3β.I n
fact, long-term oxidative stress causes GSK-3β activation
and reduces nuclear Nrf2, suggestive of downregulation
of the Nrf2-ARE pathway [82]. This hypothesis is further
supported by the ﬁnding that pharmacological treatments,
which inhibit GSK-3β, have been reported to reduce Aβ
pathology and cognitive impairment in AD mice [24].
M o r e o v e r ,l i t h i u m ,aG S K - 3 β inhibitor, has been shown to
promote the transcriptional activity of Nrf2 [82].
While modulating the activity of GSK-3β is known to
be beneﬁcial in models of AD, studying the mechanism of
action of modulators of the kinase is important in under-
standing the diverse pathways GSK-3β is involved in and
the numerous eﬀects modulation may have. For example,
treatment with small molecules such as PDTC prevents
cognitive impairment in transgenic AD mice [106], not only
by the inhibition of GSK-3β, but also potentially via the
activation of the Nrf2-ARE pathway.
8. Concluding Remarks
Due to the major social and economical burden caused
by the aging of populations and the subsequent increase
in the incidences of neurodegenerative diseases, potential
novel targets for eﬀective AD therapeutics are urgently
needed. Despite extensive research and knowledge that
oxidativestressisacentralpathologicalfeatureofAD,several
therapeutic approaches targeted to this aspect of disease have
failed, most likely because they have targeted only one aspect
such as the decline of a single antioxidant. Considering the
complexity of the antioxidant system, it seems reasonable
to consider that the induction of endogenous protective
pathways, such as the Nrf2-ARE pathway against oxidative
stress, is a viable strategy for delaying the progression of
injury and cell death.
It is clear that understanding the mechanisms of regula-
tion of the Nrf2-ARE pathway and how these mechanisms
are impaired in disease is central in deciphering how we
can modulate this protective pathway against oxidative stress
associated with AD. While several other regulatory pathways
of Nrf2-ARE have been described and GSK-3β modulation
in AD is also known to be beneﬁcial in several ways,
studying the inﬂuence of GSK-3β on Nrf2-ARE is certainly
an important path to pursue in order to better understand
how to combat the oxidative stress associated with AD.
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